Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01851369
Recruitment Status : Recruiting
First Posted : May 10, 2013
Last Update Posted : December 10, 2019
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )